GSK’s RSV Shot Wins Expanded US Approval Amid Vaccine Pressure

GSK Plc’s vaccine to protect against a dangerous respiratory virus won expanded US approval to cover all high-risk adults, a reassuring move for drugmakers given the Trump administration’s increased scrutiny of immunizations.

The shot, called Arexvy, already has US Food and Drug Administration approval for all adults aged 60 and over and those aged 50 to 59 with at least one health condition that puts them at risk of severe infection. The new approval will expand the eligible population by around 21 million adults in the US and put Arexvy on par with a rival vaccine from Pfizer Inc.